Trastuzumab and ECG Changes Dilemma
,
Abstract
No Abstract No Abstract No Abstract
1. Anjos M, Fontes-Oliveira M, Costa VM, et al. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life Sci. 2021;280:119760.
2. Olorundare OE, Adeneye AA, Akinsola AO, et al. Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity. Front Pharmacol. 2021;11:610331.
3. Vazdar L, Gabric ID, Kruljac I, et al. Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer. Sci Rep. 2021;11(1):14395.
4. Elme A, Saarto T, Totterman KJ, et al. Electrocardiography changes during adjuvant breast cancer therapy: incidence and risk factors. Anticancer Res. 2013;33(11):4933-9.
5. Piotrowski G, Gawor R, Stasiak A, et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci. 2012;8(2):227-35.
6. Karaca M, Kocoglu H, Bilgetekin I, et al. Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect. J Cancer Res Ther. 2018;14(Supplement):S536-S537.
2. Olorundare OE, Adeneye AA, Akinsola AO, et al. Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity. Front Pharmacol. 2021;11:610331.
3. Vazdar L, Gabric ID, Kruljac I, et al. Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer. Sci Rep. 2021;11(1):14395.
4. Elme A, Saarto T, Totterman KJ, et al. Electrocardiography changes during adjuvant breast cancer therapy: incidence and risk factors. Anticancer Res. 2013;33(11):4933-9.
5. Piotrowski G, Gawor R, Stasiak A, et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 - a prospective study. Arch Med Sci. 2012;8(2):227-35.
6. Karaca M, Kocoglu H, Bilgetekin I, et al. Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect. J Cancer Res Ther. 2018;14(Supplement):S536-S537.
| Files | ||
| Issue | Vol 17, No 2 (2023) | |
| Section | Editorial | |
| DOI | https://doi.org/10.18502/ijhoscr.v17i2.12641 | |
| Keywords | ||
| ECG Changes; Trastuzumab; Herceptin; Cardiotoxicity | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Alizadehasl A, Mohseni M, Noohi Bezanjani F, Maleki M, Roudini K. Trastuzumab and ECG Changes Dilemma. Int J Hematol Oncol Stem Cell Res. 2023;17(2):63-64.
